Kiora Pharmaceuticals INC 10-Q quarterly reports

Kiora Pharmaceuticals, Inc. (KPRX) filed its Form 10-Q for the quarter ended June 30, 2026, detailing progress in its clinical-stage retinal disease programs, strategic collaborations, and financial position.

Kiora Pharmaceuticals reports a net loss of $2.42 million for Q1 2026, with cash reserves projected to fund operations into late 2028 following a recent financing.

Kiora Pharmaceuticals reports Q3 2025 results, highlighting progress in KIO-301 and KIO-104 clinical trials and extending its cash runway into late 2027.

Kiora Pharmaceuticals reported a net loss for Q2 2025, contrasting with prior year's income, while advancing its KIO-301 and KIO-104 ophthalmic drug candidates into Phase 2 trials and securing a new option agreement.

Kiora Pharmaceuticals reports a net loss of $2.19 million for Q1 2025, compared to a net income of $13.45 million in Q1 2024, primarily due to the recognition of collaboration revenue in the prior year and increased R&D expenses.

Kiora Pharmaceuticals reported a net income of $7.8 million for the nine months ended September 30, 2024, driven by a $16 million upfront payment from a strategic collaboration.

Kiora Pharmaceuticals reports a significant increase in revenue and a net income of $11.2 million for the six months ended June 30, 2024, primarily due to a $16 million upfront payment from a strategic collaboration.

Kiora Pharmaceuticals reported a significant increase in revenue for the first quarter of 2024, primarily due to a $16 million upfront payment from a licensing agreement.